OncoC4, Inc. Announces Successful Closure of $50 Million Series B Financing Round

OncoC4, Inc., a clinical-stage biotechnology company based in Rockville, Maryland, has recently concluded a Series B financing round, securing close to $50 million. The financing was spearheaded by GBA Fund and saw additional contributions from the company's co-founders, existing investors including HM Capital, 3E Bioventures Capital, and Kaitai Capital.

Founded in 2020 by renowned immunologists and serial entrepreneurs, Dr. Yang Liu and Dr. Pan Zheng, OncoC4 has focused on leveraging its expertise in immuno-oncology and translational medicine to develop a wide range of innovative therapies with significant potential. The funds from the Series B financing will primarily bolster the clinical development of the company's pipeline programs. Dr. Yang Liu, Co-Founder, Chairman of the Board, CEO, and CSO of OncoC4, expressed gratitude for the rapid progress of the financing round and reiterated the company's commitment to advancing their pipeline globally and expanding business development activities.

OncoC4, headquartered in Rockville, Maryland, is dedicated to discovering and developing novel biologics for potential cancer and neurodegenerative disease treatment. The company's pipeline comprises assets targeting both novel and well-validated targets across oncology and immunological diseases.